| Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis A Visram, C Vachon, LB Baughn, D Larson, J Smadbeck, A Dispenzieri, ... Leukemia, 2024 | | 2024 |
| Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design I Vaxman, SK Kumar, F Buadi, MQ Lacy, D Dingli, Y Hwa, A Fonder, ... Leukemia, 2024 | | 2024 |
| First relapse in patients with multiple myeloma: Outcomes and predictors. S Seth, P Kapoor, F Buadi, M Binder, J Cook, A Dispenzieri, D Dingli, ... Journal of Clinical Oncology 42 (16_suppl), 7558-7558, 2024 | | 2024 |
| Class comparison of BCMA-directed therapies in relapsed multiple myeloma. RJ Matthew, A Mammadzadeh, A Bolarinwa, ME Elhaj, A Bohra, ... Journal of Clinical Oncology 42 (16_suppl), 7515-7515, 2024 | | 2024 |
| Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). Y Wang, BR LaPlant, SA Parikh, JF Leis, TG Call, TD Shanafelt, R He, ... Journal of Clinical Oncology 42 (16_suppl), 7050-7050, 2024 | | 2024 |
| Cardiac complete response in AL amyloidosis has similar survival to matched general population E Muchtar, S Geyer, G Merlini, MA Gertz Blood Journal, blood. 2024024623, 2024 | | 2024 |
| Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia S Zanwar, J Le-Rademacher, E Durot, S D’Sa, JP Abeykoon, P Mondello, ... Journal of Clinical Oncology, JCO. 23.02066, 2024 | | 2024 |
| Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. S Kumar, M Rees, A Mammadzadeh, A Bolarinwa, M Elhaj, A Bohra, ... | | 2024 |
| Peripheral Neuropathy in AL Amyloidosis: Clinical Presentations and Outcomes of Current Therapies (S21. 008) P Chompoopong, E Muchtar, M Mauermann Neurology 102 (17_supplement_1), 3291, 2024 | | 2024 |
| Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures S Zanwar, MA Gertz, E Muchtar, FK Buadi, T Kourelis, W Gonsalves, ... Leukemia, 1-4, 2024 | 2 | 2024 |
| Artificial intelligence electrocardiography to predict atrial fibrillation in patients with chronic lymphocytic leukemia G Christopoulos, ZI Attia, SJ Achenbach, KG Rabe, TG Call, W Ding, ... Cardio Oncology 6 (2), 251-263, 2024 | 1 | 2024 |
| A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis C Charalampous, S Dasari, E McPhail, JD Theis, JA Vrana, A Dispenzieri, ... Kidney international 105 (3), 484-495, 2024 | 3 | 2024 |
| Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma S Goldman-Mazur, A Visram, SV Rajkumar, P Kapoor, A Dispenzieri, ... Clinical Lymphoma Myeloma and Leukemia 24 (3), e104-e111. e1, 2024 | | 2024 |
| Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study R Goldis, B Kaplan, M Arad, A Dispenzieri, S Dasari, OL Kukuy, AJ Simon, ... Clinical Chemistry and Laboratory Medicine (CCLM) 62 (3), 464-471, 2024 | | 2024 |
| The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients E Muchtar, V Sanchorawala, H Hassan, U Hegenbart, S Schonland, ... Blood 142 (Supplement 1), 4784-4784, 2023 | 1 | 2023 |
| Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas U Yadav, SK Kumar, LB Baughn, A Dispenzieri, P Greipp, R Ketterling, ... Blood 142 (22), 1871-1878, 2023 | 3 | 2023 |
| Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL) PJ Hampel, KG Rabe, Y Wang, SS Kenderian, W Ding, E Muchtar, JF Leis, ... Blood 142, 3276, 2023 | | 2023 |
| Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia S Zanwar, J Le-Rademacher, E Durot, S D'Sa, JP Abeykoon, P Mondello, ... Blood 142, 3030, 2023 | 1 | 2023 |
| Blood-Based Diagnostic Assay for λ Light Chain Amyloidosis through Quantification of an Amyloidogenicity-Indicating Neo-Epitope X Jiang, J Wang, YC Li, AB Jackman, H Flaherty, I Rogers, E Muchtar, ... Blood 142, 536, 2023 | 2 | 2023 |
| Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment S Kosydar, KG Rabe, Y Wang, SS Kenderian, W Ding, E Muchtar, JF Leis, ... Blood 142, 3284, 2023 | | 2023 |
Angela DispenzieriMayo Clinic在 mayo.edu 的电子邮件经过验证
